Angitia Biopharmaceuticals ยท 2 months ago
Director, Clinical Quality Assurance
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. The Director of Clinical Quality Assurance will be responsible for ensuring quality and compliance of Angitia sponsored clinical studies and GLP studies, while working closely with various teams to cultivate a culture of quality and compliance across the organization.
Biotechnology
Responsibilities
Drive and cultivate a culture of quality throughout the company to help ensure compliance with all applicable regulations, guidelines, and corporate standards, policies, and procedures
Provide QA oversight and support to internal staff in support of Angitia sponsored clinical studies and GLP studies
Development and management of processes and controlled documents related to Angitia sponsored clinical studies (clinical operations, clinical development, pharmacovigilance, regulatory) and GLP studies (translational medicine)
Prepare for health authority audit readiness
Develop phase-appropriate Clinical QA operating models in accordance with ICH risk-based compliance guidance; set a strong foundation for future commercial operations
Develop and implement audit plans and schedule for clinical study vendors and other study related GxP vendors (CROs, central /specialty labs, imaging, etc.)
Oversee and/or perform site and vendor audits to assure quality assurance compliance with regards to all internal as well as applicable regulatory guidelines
Lead selection of contract auditors to perform site and vendor audits as needed
Ensure timely and effective follow up to all identified or assigned quality issues
Conduct QA review of Angitia sponsored clinical study documents, internal controlled documents and vendor documents
Train internal staff on regulatory requirements such as GCP training
Ensure training compliance and completion for Clinical Development, and potentially others
Identify critical compliance and/or business issues related to GxP, CROs, Contract Test Laboratories and manufacturers of critical starting materials. Create and execute remediation strategies and tactical plans as needed using a risk-based approach
Develop and oversee study quality metrics for clinical studies including study risk assessment, mitigation and CAPA management
Coordinate and host all FDA and Health Authority inspections
Ensure all Quality agreements are effectively negotiated to meet the near- and long-term needs of Angitia as agreed with legal, finance and functional heads
May require up to 25% travel
Qualification
Required
BS BA (or equivalent) in a relevant scientific discipline
10+ years of Biotechnology industry with at least 8-12 years' experience in Quality Assurance, or equivalent levels of education and / or experience
Strong knowledge of GCP, GLP, and ICH clinical study requirements
Experience with both domestic and international clinical studies (CDE, EMA and FDA regulations)
Experience building a quality program and quality system in young, science-driven organizations
Experience leading audits of GXP vendors as well as clinical sites
Demonstrated problem-solving and critical thinking skills
Excellent interpersonal, written and verbal communication skills
Excellent computer skills in the following programs: MS Word, PowerPoint, Excel. And others
Able to travel domestically and internationally up to 25% of the time
Preferred
Advanced degree desirable
Benefits
Medical, dental, and vision coverage for employees and their eligible dependents
401(K) Retirement Plan with Company match
Company paid Long Term Disability Coverage
Company-paid life Insurance & AD&D Coverage
Voluntary Life Insurance & AD&D Coverage
Employee Assistance Program (EAP)
Company-paid Holidays
Vacation
Paid Sick Leave
Telecommunication Monthly Stipend
Work-From-Home Equipment Reimbursement
Company
Angitia Biopharmaceuticals
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases.
Funding
Current Stage
Growth StageRecent News
2024-01-19
2023-12-19
BioWorld Financial Watch
2023-10-30
Company data provided by crunchbase